A clinicopathological and molecular series of five TFEB-altered renal cell carcinoma (RCC) cases: highlighting an aggressive subset of TFEB-rearranged RCC concomitant with TFEB amplification/gene copy number gains.

IF 3.4 3区 医学 Q1 PATHOLOGY Virchows Archiv Pub Date : 2024-11-10 DOI:10.1007/s00428-024-03968-5
Minhua Yan, Ruifen Wang, Wenbin Guan, Ruiqi Jiang, Kezhou Wang, Yi Liu, Lifeng Wang
{"title":"A clinicopathological and molecular series of five TFEB-altered renal cell carcinoma (RCC) cases: highlighting an aggressive subset of TFEB-rearranged RCC concomitant with TFEB amplification/gene copy number gains.","authors":"Minhua Yan, Ruifen Wang, Wenbin Guan, Ruiqi Jiang, Kezhou Wang, Yi Liu, Lifeng Wang","doi":"10.1007/s00428-024-03968-5","DOIUrl":null,"url":null,"abstract":"<p><p>The classification of TFEB-altered renal cell carcinoma (RCC) has been revised to include TFEB-rearranged RCC and TFEB-amplified RCC in the 2022 World Health Organization (WHO) Classification of Tumors of the Urinary System. Given the wide spectrum of TFEB-altered RCC in terms of morphology and clinical behavior, an accurate diagnosis is challenging yet crucial, particularly in aggressive cases. Moreover, the concurrence of TFEB gene rearrangement and amplification/gene copy number (GCN) gains was also observed, but there was limited knowledge of these cases. We presented three TFEB-rearranged RCC cases, one TFEB-amplified RCC case, and one case of concomitant TFEB-rearranged and -amplified RCC, comparing the similarities and differences among these three subgroups. Furthermore, we summarized the clinicopathological and molecular features of TFEB-rearranged RCC concomitant with TFEB amplification/GCN gains from the literature and the present study. TFEB-altered RCCs exhibit significant heterogeneity in morphology and clinical behavior while displaying similar immunohistochemical profiles, including positive staining for Melan-A, PAX8, and CD117, and negative staining for CK7. A typical biphasic \"rosette-like\" morphology has been observed in a proportion of TFEB-rearranged RCC concomitant with TFEB amplification/GCN gains, which has been noted in TFEB-rearranged RCC, but not in cases with only TFEB amplification. Notably, TFEB-rearranged RCCs concomitant with TFEB amplification/GCN gains tend to be aggressive, in contrast to the often indolent nature of TFEB-rearranged cases, irrespective of the extent of TFEB gene copy increase. Therefore, a TFEB FISH assay is essential for unclassified RCC cases that exhibit melanocytic marker expression, and fluorescent signals should be counted and interpreted acurrately.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-024-03968-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The classification of TFEB-altered renal cell carcinoma (RCC) has been revised to include TFEB-rearranged RCC and TFEB-amplified RCC in the 2022 World Health Organization (WHO) Classification of Tumors of the Urinary System. Given the wide spectrum of TFEB-altered RCC in terms of morphology and clinical behavior, an accurate diagnosis is challenging yet crucial, particularly in aggressive cases. Moreover, the concurrence of TFEB gene rearrangement and amplification/gene copy number (GCN) gains was also observed, but there was limited knowledge of these cases. We presented three TFEB-rearranged RCC cases, one TFEB-amplified RCC case, and one case of concomitant TFEB-rearranged and -amplified RCC, comparing the similarities and differences among these three subgroups. Furthermore, we summarized the clinicopathological and molecular features of TFEB-rearranged RCC concomitant with TFEB amplification/GCN gains from the literature and the present study. TFEB-altered RCCs exhibit significant heterogeneity in morphology and clinical behavior while displaying similar immunohistochemical profiles, including positive staining for Melan-A, PAX8, and CD117, and negative staining for CK7. A typical biphasic "rosette-like" morphology has been observed in a proportion of TFEB-rearranged RCC concomitant with TFEB amplification/GCN gains, which has been noted in TFEB-rearranged RCC, but not in cases with only TFEB amplification. Notably, TFEB-rearranged RCCs concomitant with TFEB amplification/GCN gains tend to be aggressive, in contrast to the often indolent nature of TFEB-rearranged cases, irrespective of the extent of TFEB gene copy increase. Therefore, a TFEB FISH assay is essential for unclassified RCC cases that exhibit melanocytic marker expression, and fluorescent signals should be counted and interpreted acurrately.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
五例TFEB改变的肾细胞癌(RCC)的临床病理和分子系列研究:突显了伴随TFEB扩增/基因拷贝数增加的TFEB重排RCC的侵袭性亚群。
在2022年世界卫生组织(WHO)的泌尿系统肿瘤分类中,TFEB改变的肾细胞癌(RCC)的分类已被修订为包括TFEB重组的RCC和TFEB扩增的RCC。鉴于TFEB改变的RCC在形态和临床表现方面的广泛性,准确诊断具有挑战性,但也至关重要,尤其是在侵袭性病例中。此外,还观察到 TFEB 基因重排和扩增/基因拷贝数(GCN)增高并存的情况,但对这些病例的了解有限。我们介绍了三例TFEB基因重排的RCC病例、一例TFEB基因扩增的RCC病例和一例同时存在TFEB基因重排和扩增的RCC病例,比较了这三个亚组的异同。此外,我们还从文献和本研究中总结了TFEB改变的RCC同时伴有TFEB扩增/GCN增益的临床病理和分子特征。TFEB改变的RCC在形态和临床表现上表现出明显的异质性,同时显示出相似的免疫组化特征,包括Melan-A、PAX8和CD117阳性染色和CK7阴性染色。在一部分 TFEB 重排的 RCC 中观察到典型的双相 "花环样 "形态,同时伴有 TFEB 扩增/GCN 增益,这在 TFEB 重排的 RCC 中已被注意到,但在仅有 TFEB 扩增的病例中却没有发现。值得注意的是,无论 TFEB 基因拷贝增加的程度如何,TFEB 重组的 RCC 同时伴有 TFEB 扩增/GCN 基因增殖往往具有侵袭性,而 TFEB 重组的病例则往往不具侵袭性。因此,对于表现出黑色素细胞标记表达的未分类 RCC 病例,TFEB FISH 检测是必不可少的,而且应准确计算和解释荧光信号。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Virchows Archiv
Virchows Archiv 医学-病理学
CiteScore
7.40
自引率
2.90%
发文量
204
审稿时长
4-8 weeks
期刊介绍: Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.
期刊最新文献
Heterogeneity of pancreatic neoplasms arising in pancreatic heterotopia: a single institution review. Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review. A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor. Expanding horizons in a new era for pathology: perspectives from the ASCO meeting. Low CXCL11 expression is indicative of poor prognosis in rectal cancer patients undergoing preoperative chemoradiotherapy: a retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1